Core Viewpoint - Micron Heart Technology-B (02160.HK) has reported significant growth in the adoption of its VitaFow® series transcatheter aortic valves and delivery systems (TAVI), with a projected increase in implant volume for 2025 [1] Group 1: Product Performance - The VitaFow® series TAVI has been introduced in 35 countries and regions globally, with a cumulative implant volume nearing 1,300 cases [1] - The implant volume for 2025 is expected to exceed 850 cases, representing a nearly 350% increase compared to 2024 [1] - In the second half of 2025, the implant volume is anticipated to grow by over 170% compared to the first half, driven by the commercialization of VitaFow Liberty® following CE certification in European countries [1] Group 2: Market Expansion - The company is focusing on expanding its market share in emerging markets in Asia and Latin America, contributing to the anticipated growth in implant volumes [1]

Group 1 - The core point of the news highlights the top short-selling stocks in the market, with Hang Seng Bank-R, Sun Hung Kai Properties-R, and Lenovo Group-R leading in short-selling ratios at 100% each [1][2] - Alibaba-W, China Merchants Bank, and Baidu Group have the highest short-selling amounts, with figures of 1.242 billion, 1.018 billion, and 746 million respectively [1][2] - The deviation values for Hang Seng Bank-R, Hong Kong Exchanges-R, and Alibaba-W are the highest, recorded at 61.59%, 55.31%, and 48.34% respectively [1][2] Group 2 - The top ten short-selling ratio rankings show that Hang Seng Bank-R, Sun Hung Kai Properties-R, and Lenovo Group-R all have a short-selling ratio of 100% [2] - The top ten short-selling amounts list indicates Alibaba-W leading with 1.242 billion, followed by China Merchants Bank at 1.018 billion and Baidu Group at 746 million [2] - The top ten deviation values list features Hang Seng Bank-R with a deviation of 61.59%, followed by Hong Kong Exchanges-R at 55.31% and Alibaba-W at 48.34% [2]

Major Events - Cloudtop New Horizon (01952) has its original product, Nanfukang®, protected by patent ZL200980127272.5 in China, which is currently valid [1] - Linkang Biotechnology Group (00690) has reached a strategic cooperation with Wenzhou Medical University National Engineering Research Center and the People's Government of Ouhai District, Wenzhou [1] - Auhua Pharmaceutical (00013) announced that the new drug application for Savolitinib for treating gastric cancer patients with MET amplification has been accepted and included in priority review in China [1] - Fosun Pharma (02196) has initiated Phase I clinical trials for its integrated diagnosis and treatment nuclear medicine project SRT-007 within China [1] - Postal Savings Bank of China (01658) has received approval from the National Financial Supervision Administration for the absorption and merger with Postal Huai Wanjia Bank [1] - MicroPort Cardiac Devices-B (02160) has officially published the one-year follow-up results of the early feasibility study for AltaValveTM [1] Operating Performance - New Fire Technology Holdings (01611) reported an annual loss attributable to shareholders of HKD 9.212 million, a shift from profit to loss year-on-year [1] - Xingqian Development (00640) reported an annual net profit of approximately HKD 122 million, an increase of 21.7% year-on-year [1] - Zijin Mining Group (02899) expects a net profit attributable to shareholders of approximately RMB 51-52 billion for the fiscal year 2025, representing a year-on-year increase of about 59%-62% [1] - Zijin Gold International (02259) issued a profit warning, expecting a net profit attributable to shareholders of approximately USD 1.5-1.6 billion for 2025, a year-on-year increase of about 212%-233% [1]

Core Viewpoint - The company, HeartLink Medical-B (02160.HK), has announced significant growth in its VitaFow® series of transcatheter aortic valves and delivery systems (TAVI), with a cumulative implantation of nearly 1,300 cases across 35 countries and regions as of the announcement date [1] Group 1: Market Expansion - The projected implantation volume for 2025 is expected to exceed 850 cases, representing an increase of nearly 350% compared to 2024 [1] - In the second half of 2025, the implantation volume is anticipated to grow by over 170% compared to the first half, driven by the commercialization of VitaFowLiberty® following CE mark approval in European countries and continued market share growth in emerging markets in Asia and Latin America [1] Group 2: Strategic Enhancements - The company's board believes that the recent acquisition of Micro-Invasive Cardiac Management will strengthen local channel resources and clinical support systems in mature markets like Europe, significantly improving market access efficiency for TAVI products [1] - The company aims to continuously leverage the synergies from business integration, advance the research and clinical progress of next-generation TAVI products, and enhance its overall competitiveness in the global valve treatment sector [1]

Core Viewpoint - MicroPort CardioFlow-B (02160) has announced significant growth in its VitaFow series transcatheter aortic valves and delivery systems, with a global presence in 35 countries and nearly 1,300 implants to date [1] Group 1: Market Expansion - The company expects to exceed 850 implants in 2025, representing a nearly 350% increase compared to 2024 [1] - In the second half of 2025, the implant volume is projected to grow by over 170% compared to the first half, driven by the commercialization of VitaFow Liberty in Europe following CE certification and increased market share in emerging markets in Asia and Latin America [1] Group 2: Strategic Development - The board believes that the recent acquisition of MicroPort Cardiac Rhythm Management will enhance local channel resources and clinical support systems in mature markets like Europe, significantly improving market access efficiency for TAVI products [1] - The company aims to continuously leverage the synergies from business integration, advancing the research and clinical progress of next-generation TAVI products, and enhancing its comprehensive competitiveness in the global valve treatment sector [1]

Core Insights - The early feasibility study results for the AltaValve™ transcatheter mitral valve replacement (TMVR) device developed by 4C Medical Technologies, Inc. have been published, showing promising outcomes for high-risk patients with symptomatic severe mitral regurgitation (MR) [1] Group 1: Study Results - The study included 30 high-risk patients across Europe, the United States, and Japan, with 13 patients undergoing the transapical approach and 17 patients undergoing the transseptal approach [1] - The procedural success rate was reported at 97%, with complete elimination of MR in all patients [1] - The mean transvalvular pressure gradient decreased from 2.5 mmHg at baseline to 2.1 mmHg post-procedure, indicating significant improvement in cardiac hemodynamics [1] - 96% of patients improved to NYHA functional class I-II after one year, reflecting a substantial enhancement in quality of life [1] Group 2: Safety and Mortality - The one-year all-cause mortality rate was 17% for the transapical group and only 7% for the transseptal group, with no cases of cardiac-related mortality [1] - There were no adverse events such as stroke, new-onset atrial fibrillation, or re-intervention on the mitral valve reported in the entire cohort [1] Group 3: Regulatory Approval - AltaValve™ received two breakthrough device designations from the FDA in 2024 and is currently conducting pivotal clinical studies in Europe and the United States under an FDA-approved Investigational Device Exemption (IDE) [2]

Core Viewpoint - The announcement highlights the successful one-year follow-up results of the early feasibility study for the AltaValveTM transcatheter mitral valve replacement (TMVR) device developed by 4C Medical Technologies, Inc., indicating significant improvements in patient outcomes and safety [1] Group 1: Study Overview - The study involved 30 high-risk patients with symptomatic severe mitral regurgitation (MR) across multiple centers in Europe, the USA, and Japan [1] - Patients were divided into two groups: 13 underwent the transapical approach, while 17 used the transseptal approach [1] Group 2: Clinical Outcomes - The technical success rate of the procedure was reported at 97%, with complete elimination of MR in all patients [1] - The mean transvalvular pressure gradient decreased from 2.5 mmHg at baseline to 2.1 mmHg post-operation, indicating significant hemodynamic improvement [1] Group 3: Safety Profile - The one-year all-cause mortality rate was 17% for the transapical group and only 7% for the transseptal group, with no cases of cardiac-related mortality [1] - No adverse events such as stroke, new-onset atrial fibrillation, or mitral valve re-intervention were reported in the entire cohort [1] Group 4: Quality of Life Improvement - 96% of patients improved to NYHA functional class I-II at one year, reflecting a substantial enhancement in quality of life [1] Group 5: Regulatory Status - AltaValveTM received two breakthrough device designations from the FDA in 2024 and is currently conducting pivotal clinical studies in Europe and the USA under an FDA-approved Investigational Device Exemption (IDE) [1]

Core Insights - The early feasibility study results for the AltaValveTM transcatheter mitral valve replacement (TMVR) device developed by 4C Medical Technologies, Inc. have been published, showing promising outcomes in high-risk patients with symptomatic severe mitral regurgitation (MR) [1][2] Group 1: Study Results - The study included 30 patients across Europe, the United States, and Japan, all of whom were at high surgical risk and had symptomatic severe MR [1] - The technical success rate of the procedure was reported at 97%, with complete elimination of MR in all patients [1] - The mean transvalvular pressure gradient decreased from 2.5 mmHg at baseline to 2.1 mmHg post-procedure, indicating significant improvement in cardiac hemodynamics [1] Group 2: Safety and Outcomes - The one-year all-cause mortality rate was 17% for the transapical group and only 7% for the transseptal group, with no cases of cardiac-related mortality [1] - There were no adverse events such as stroke, new-onset atrial fibrillation, or re-intervention on the mitral valve reported in the entire cohort [1] - 96% of patients improved to NYHA functional class I-II at one year, reflecting a substantial enhancement in quality of life [1] Group 3: Regulatory Status - AltaValveTM has received two breakthrough device designations from the FDA in 2024 and is currently undergoing pivotal clinical studies in Europe and the United States under an FDA-approved Investigational Device Exemption (IDE) [2]

Core Viewpoint - MicroPort CardioFlow-B (02160) has announced significant growth in its VitaFow® transcatheter aortic valve and delivery system, with a cumulative implantation of nearly 1,300 cases across 35 countries and regions as of the announcement date [1] Group 1: Market Expansion - The company expects the implantation volume to exceed 850 cases in 2025, representing an increase of nearly 350% compared to 2024 [1] - In the second half of 2025, the implantation volume is projected to grow by over 170% compared to the first half, driven by the commercialization of VitaFow Liberty® in European countries following CE certification and increased market share in emerging markets in Asia and Latin America [1] Group 2: Strategic Development - The board believes that the recent acquisition of MicroPort Cardiac Rhythm Management will enhance local channel resources and clinical support systems in mature markets like Europe, significantly improving market access efficiency for TAVI products [1] - The company aims to continuously leverage the synergies from business integration, advancing the research and clinical progress of next-generation TAVI products, and enhancing its comprehensive competitiveness in the global valve treatment field [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 本公告乃由微創心通醫療科技有限公司（「本公司」，連同其附屬公司統稱「本 集團」）自願作出，以知會本公司股東及潛在投資者有關本集團最新業務進展。 本公司董事「( 董 事」)會（「董事會」）欣 然 宣 佈， 截 至 本 公 告 之 日， 本 集 團 VitaFow®系列經導管主動脈瓣膜及輸送系統（「TAVI」）已進入全球35個國家及地 區，累計植入量近1,300例。其中，2025年植入量預計將超過850例，較2024年增 長近350%。2025年下半年，得益於VitaFow Liberty®獲得CE證後在歐洲國家商業 化的持續拓展，以及在亞洲和拉美新興市場國家份額的持續提升，植入量較上 半年增長超過170%。 – 1 – 本公司董事會相信，通過近期完成的併購微創心律管理的交易，本集團將進一 步強化在歐洲等成熟市場的本地化渠道資源與臨床支持體系，顯著提升TAVI 產品的新市場准入效率與既有市場的滲透深度。未來 ...